{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T02:38:49Z","timestamp":1785465529928,"version":"3.56.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,3,24]],"date-time":"2024-03-24T00:00:00Z","timestamp":1711238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,24]],"date-time":"2024-03-24T00:00:00Z","timestamp":1711238400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1245\/s10434-024-15182-3","type":"journal-article","created":{"date-parts":[[2024,3,24]],"date-time":"2024-03-24T17:01:39Z","timestamp":1711299699000},"page":"4477-4486","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Implementation of the Targeted Axillary Dissection Procedure in Clinically Node-Positive Breast Cancer: A Retrospective Analysis"],"prefix":"10.1245","volume":"31","author":[{"given":"Joni J.","family":"Nijveldt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7337-2911","authenticated-orcid":false,"given":"Kiran K.","family":"Rajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karina","family":"Boersma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva M.","family":"Noorda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"van der Starre-Gaal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miranda van \u2019t Veer-ten","family":"Kate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen M. A.","family":"Roeloffzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian N.","family":"Vendel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten A.","family":"Beek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Brecht","family":"Francken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,24]]},"reference":[{"issue":"3","key":"15182_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"issue":"Supplement 1","key":"15182_CR2","doi-asserted-by":"publisher","first-page":"9S","DOI":"10.2967\/jnumed.115.157834","volume":"57","author":"ES McDonald","year":"2016","unstructured":"McDonald ES, Clark AS, Tchou J, Zhang P, Freedman GM. Clinical diagnosis and management of breast cancer. J Nucl Med. 2016;57(Supplement 1):9S-16S. https:\/\/doi.org\/10.2967\/jnumed.115.157834.","journal-title":"J Nucl Med"},{"issue":"10","key":"15182_CR3","doi-asserted-by":"publisher","first-page":"6163","DOI":"10.1245\/s10434-022-12133-8","volume":"29","author":"KuG De la Cruz","year":"2022","unstructured":"De la Cruz KuG, Karamchandani M, Chambergo-Michilot D, et al. Does breast-conserving surgery with radiotherapy have a better survival than mastectomy? A meta-analysis of more than 1,500,000 patients. Ann Surg Oncol. 2022;29(10):6163\u201388. https:\/\/doi.org\/10.1245\/s10434-022-12133-8.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"15182_CR4","doi-asserted-by":"publisher","first-page":"6","DOI":"10.4274\/ejbh.galenos.2021.2021-5-4","volume":"18","author":"U Wazir","year":"2021","unstructured":"Wazir U, Mokbel K. De-escalation of breast cancer surgery following neoadjuvant systemic therapy. Eur J Breast Health. 2021;18(1):6\u201312. https:\/\/doi.org\/10.4274\/ejbh.galenos.2021.2021-5-4.","journal-title":"Eur J Breast Health"},{"issue":"15","key":"15182_CR5","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1002\/cncr.29348","volume":"121","author":"SS Mougalian","year":"2015","unstructured":"Mougalian SS, Soulos PR, Killelea BK, et al. Use of neoadjuvant chemotherapy for patients with stage I to III breast cancer in the United States. Cancer. 2015;121(15):2544\u201352. https:\/\/doi.org\/10.1002\/cncr.29348.","journal-title":"Cancer"},{"issue":"14","key":"15182_CR6","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1016\/j.ejca.2011.06.014","volume":"47","author":"X Kong","year":"2011","unstructured":"Kong X, Moran MS, Zhang N, Haffty B, Yang Q. Meta-analysis confirms achieving pathological complete response after neoadjuvant chemotherapy predicts favourable prognosis for breast cancer patients. Eur J Cancer. 2011;47(14):2084\u201390. https:\/\/doi.org\/10.1016\/j.ejca.2011.06.014.","journal-title":"Eur J Cancer"},{"issue":"4","key":"15182_CR7","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1245\/s10434-020-09480-9","volume":"28","author":"RA Leon-Ferre","year":"2021","unstructured":"Leon-Ferre RA, Hieken TJ, Boughey JC. The Landmark Series: Neoadjuvant chemotherapy for triple-negative and HER2-positive breast cancer. Ann Surg Oncol. 2021;28(4):2111\u20139. https:\/\/doi.org\/10.1245\/s10434-020-09480-9.","journal-title":"Ann Surg Oncol"},{"key":"15182_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2021.103223","volume":"159","author":"P Tarantino","year":"2021","unstructured":"Tarantino P, Gandini S, Trapani D, Criscitiello C, Curigliano G. Immunotherapy addition to neoadjuvant chemotherapy for early triple negative breast cancer: a systematic review and meta-analysis of randomized clinical trials. Crit Rev Oncol Hematol. 2021;159:103223. https:\/\/doi.org\/10.1016\/j.critrevonc.2021.103223.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"15182_CR9","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S1470-2045(21)00589-1","volume":"23","author":"C Yau","year":"2022","unstructured":"Yau C, Osdoit M, van der Noordaa M, et al. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. Lancet Oncol. 2022;23(1):149\u201360. https:\/\/doi.org\/10.1016\/S1470-2045(21)00589-1.","journal-title":"Lancet Oncol."},{"issue":"6","key":"15182_CR10","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1053\/j.seminoncol.2020.09.001","volume":"47","author":"F Magnoni","year":"2020","unstructured":"Magnoni F, Galimberti V, Corso G, Intra M, Sacchini V, Veronesi P. Axillary surgery in breast cancer: an updated historical perspective. Semin Oncol. 2020;47(6):341\u201352. https:\/\/doi.org\/10.1053\/j.seminoncol.2020.09.001.","journal-title":"Semin Oncol"},{"issue":"9","key":"15182_CR11","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1093\/jnci\/djj158","volume":"98","author":"RE Mansel","year":"2006","unstructured":"Mansel RE, Fallowfield L, Kissin M, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC trial. JNCI J Natl Cancer Inst. 2006;98(9):599\u2013609. https:\/\/doi.org\/10.1093\/jnci\/djj158.","journal-title":"JNCI J Natl Cancer Inst"},{"issue":"13","key":"15182_CR12","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1002\/bjs.9955","volume":"102","author":"MA Beek","year":"2015","unstructured":"Beek MA, Verheuvel NC, Luiten EJT, et al. Two decades of axillary management in breast cancer. Br J Surg. 2015;102(13):1658\u201364. https:\/\/doi.org\/10.1002\/bjs.9955.","journal-title":"Br J Surg"},{"issue":"3","key":"15182_CR13","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1097\/SLA.0000000000003075","volume":"269","author":"JM Simons","year":"2019","unstructured":"Simons JM, van Nijnatten TJA, van der Pol CC, Luiten EJT, Koppert LB, Smidt ML. Diagnostic accuracy of different surgical procedures for axillary staging after neoadjuvant systemic therapy in node-positive breast cancer: a systematic review and meta-analysis. Ann Surg. 2019;269(3):432. https:\/\/doi.org\/10.1097\/SLA.0000000000003075.","journal-title":"Ann Surg"},{"issue":"6","key":"15182_CR14","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2021.0891","volume":"156","author":"S Samiei","year":"2021","unstructured":"Samiei S, Simons JM, Engelen SME, et al. Axillary pathologic complete response after neoadjuvant systemic therapy by breast cancer subtype in patients with initially clinically node-positive disease: a systematic review and meta-analysis. JAMA Surg. 2021;156(6):e210891. https:\/\/doi.org\/10.1001\/jamasurg.2021.0891.","journal-title":"JAMA Surg"},{"issue":"7","key":"15182_CR15","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.3390\/cancers13071565","volume":"13","author":"M Banys-Paluchowski","year":"2021","unstructured":"Banys-Paluchowski M, Gasparri ML, de Boniface J, et al. Surgical management of the axilla in clinically node-positive breast cancer patients converting to clinical node negativity through neoadjuvant chemotherapy: current status, knowledge gaps, and rationale for the EUBREAST-03 AXSANA Study. Cancers. 2021;13(7):1565. https:\/\/doi.org\/10.3390\/cancers13071565.","journal-title":"Cancers"},{"issue":"3","key":"15182_CR16","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.soc.2017.01.013","volume":"26","author":"SA Castaneda","year":"2017","unstructured":"Castaneda SA, Strasser J. Updates in the treatment of breast cancer with radiotherapy. Surg Oncol Clin. 2017;26(3):371\u201382. https:\/\/doi.org\/10.1016\/j.soc.2017.01.013.","journal-title":"Surg Oncol Clin"},{"issue":"7","key":"15182_CR17","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1245\/s10434-010-0945-z","volume":"17","author":"ME Straver","year":"2010","unstructured":"Straver ME, Meijnen P, van Tienhoven G, et al. Sentinel node identification rate and nodal involvement in the EORTC 10981\u201322023 AMAROS Trial. Ann Surg Oncol. 2010;17(7):1854\u201361. https:\/\/doi.org\/10.1245\/s10434-010-0945-z.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"15182_CR18","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/cncr.21568","volume":"106","author":"T Kim","year":"2006","unstructured":"Kim T, Giuliano AE, Lyman GH. Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma. Cancer. 2006;106(1):4\u201316. https:\/\/doi.org\/10.1002\/cncr.21568.","journal-title":"Cancer."},{"issue":"12","key":"15182_CR19","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1016\/j.ejso.2008.01.034","volume":"34","author":"IMC van der Ploeg","year":"2008","unstructured":"van der Ploeg IMC, Nieweg OE, van Rijk MC, Vald\u00e9s Olmos RA, Kroon BBR. Axillary recurrence after a tumour-negative sentinel node biopsy in breast cancer patients: a systematic review and meta-analysis of the literature. Eur J Surg Oncol. 2008;34(12):1277\u201384. https:\/\/doi.org\/10.1016\/j.ejso.2008.01.034.","journal-title":"Eur J Surg Oncol"},{"issue":"5","key":"15182_CR20","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.ejso.2013.02.011","volume":"39","author":"DBY Fontein","year":"2013","unstructured":"Fontein DBY, van de Water W, Mieog JSD, Liefers GJ, van de Velde CJH. Timing of the sentinel lymph node biopsy in breast cancer patients receiving neoadjuvant therapy\u2014recommendations for clinical guidance. Eur J Surg Oncol. 2013;39(5):417\u201324. https:\/\/doi.org\/10.1016\/j.ejso.2013.02.011.","journal-title":"Eur J Surg Oncol"},{"issue":"8","key":"15182_CR21","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1002\/bjs.7073","volume":"97","author":"ME Straver","year":"2010","unstructured":"Straver ME, Loo CE, Alderliesten T, Rutgers EJT, Vrancken Peeters MTFD. Marking the axilla with radioactive iodine seeds (MARI procedure) may reduce the need for axillary dissection after neoadjuvant chemotherapy for breast cancer. Br J Surg. 2010;97(8):1226\u201331. https:\/\/doi.org\/10.1002\/bjs.7073.","journal-title":"Br J Surg"},{"issue":"9","key":"15182_CR22","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1002\/bjs.10555","volume":"104","author":"BB Koolen","year":"2017","unstructured":"Koolen BB, Donker M, Straver ME, et al. Combined PET\u2013CT and axillary lymph node marking with radioactive iodine seeds (MARI procedure) for tailored axillary treatment in node-positive breast cancer after neoadjuvant therapy. Br J Surg. 2017;104(9):1188\u201396. https:\/\/doi.org\/10.1002\/bjs.10555.","journal-title":"Br J Surg"},{"issue":"6","key":"15182_CR23","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1245\/s10434-018-6404-y","volume":"25","author":"MEM van der Noordaa","year":"2018","unstructured":"van der Noordaa MEM, van Duijnhoven FH, Straver ME, et al. Major reduction in axillary lymph node dissections after neoadjuvant systemic therapy for node-positive breast cancer by combining PET\/CT and the MARI procedure. Ann Surg Oncol. 2018;25(6):1512\u201320. https:\/\/doi.org\/10.1245\/s10434-018-6404-y.","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"15182_CR24","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1097\/SLA.0000000000000558","volume":"261","author":"M Donker","year":"2015","unstructured":"Donker M, Straver ME, Wesseling J, et al. Marking axillary lymph nodes with radioactive iodine seeds for axillary staging after neoadjuvant systemic treatment in breast cancer patients: the MARI procedure. Ann Surg. 2015;261(2):378. https:\/\/doi.org\/10.1097\/SLA.0000000000000558.","journal-title":"Ann Surg"},{"issue":"7","key":"15182_CR25","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.3390\/cancers13071539","volume":"13","author":"PK Swarnkar","year":"2021","unstructured":"Swarnkar PK, Tayeh S, Michell MJ, Mokbel K. The evolving role of marked lymph node biopsy (MLNB) and targeted axillary dissection (TAD) after neoadjuvant chemotherapy (NACT) for node-positive breast cancer: systematic review and pooled analysis. Cancers. 2021;13(7):1539. https:\/\/doi.org\/10.3390\/cancers13071539.","journal-title":"Cancers"},{"issue":"4","key":"15182_CR26","doi-asserted-by":"publisher","first-page":"290","DOI":"10.3322\/caac.21393","volume":"67","author":"AE Giuliano","year":"2017","unstructured":"Giuliano AE, Connolly JL, Edge SB, et al. Breast Cancer\u2014Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(4):290\u2013303. https:\/\/doi.org\/10.3322\/caac.21393.","journal-title":"CA Cancer J Clin"},{"key":"15182_CR27","unstructured":"Federatie Medisch Specialisten. Borstkanker - Algemeen - Richtlijn - Richtlijnendatabase. 2020. https:\/\/richtlijnendatabase.nl\/richtlijn\/borstkanker\/algemeen.html. Accessed 6 Sept 2023."},{"issue":"5","key":"15182_CR28","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.clbc.2017.04.006","volume":"17","author":"TJA van Nijnatten","year":"2017","unstructured":"van Nijnatten TJA, Simons JM, Smidt ML, et al. A novel less-invasive approach for axillary staging after neoadjuvant chemotherapy in patients with axillary node-positive breast cancer by combining radioactive iodine seed localization in the axilla with the sentinel node procedure (RISAS): a Dutch prospective multicenter validation study. Clin Breast Cancer. 2017;17(5):399\u2013402. https:\/\/doi.org\/10.1016\/j.clbc.2017.04.006.","journal-title":"Clin Breast Cancer"},{"issue":"11","key":"15182_CR29","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1001\/jamasurg.2022.3907","volume":"157","author":"JM Simons","year":"2022","unstructured":"Simons JM, van Nijnatten TJA, van der Pol CC, et al. Diagnostic accuracy of radioactive iodine seed placement in the axilla with sentinel lymph node biopsy after neoadjuvant chemotherapy in node-positive breast cancer. JAMA Surg. 2022;157(11):991\u20139. https:\/\/doi.org\/10.1001\/jamasurg.2022.3907.","journal-title":"JAMA Surg"},{"issue":"12","key":"15182_CR30","first-page":"551","volume":"97","author":"O Coufal","year":"2018","unstructured":"Coufal O, Zapletal O, Gabrielov\u00e1 L, Fabian P, Schneiderov\u00e1 M. Targeted axillary dissection and sentinel lymph node biopsy in breast cancer patients after neoadjuvant chemotherapy\u2014a retrospective study. Rozhl Chir. 2018;97(12):551\u20137.","journal-title":"Rozhl Chir"},{"issue":"1","key":"15182_CR31","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s10549-022-06545-z","volume":"193","author":"AA van Loevezijn","year":"2022","unstructured":"van Loevezijn AA, van der Noordaa MEM, Stokkel MPM, et al. Three-year follow-up of de-escalated axillary treatment after neoadjuvant systemic therapy in clinically node-positive breast cancer: the MARI-protocol. Breast Cancer Res Treat. 2022;193(1):37\u201348. https:\/\/doi.org\/10.1007\/s10549-022-06545-z.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"15182_CR32","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s10549-017-4157-0","volume":"163","author":"TJA van Nijnatten","year":"2017","unstructured":"van Nijnatten TJA, Simons JM, Moossdorff M, et al. Prognosis of residual axillary disease after neoadjuvant chemotherapy in clinically node-positive breast cancer patients: isolated tumor cells and micrometastases carry a better prognosis than macrometastases. Breast Cancer Res Treat. 2017;163(1):159\u201366. https:\/\/doi.org\/10.1007\/s10549-017-4157-0.","journal-title":"Breast Cancer Res Treat"},{"issue":"10","key":"15182_CR33","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1001\/jama.2017.11470","volume":"318","author":"AE Giuliano","year":"2017","unstructured":"Giuliano AE, Ballman KV, McCall L, et al. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) Randomized Clinical Trial. JAMA. 2017;318(10):918\u201326. https:\/\/doi.org\/10.1001\/jama.2017.11470.","journal-title":"JAMA"},{"issue":"10","key":"15182_CR34","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1016\/S1470-2045(18)30380-2","volume":"19","author":"V Galimberti","year":"2018","unstructured":"Galimberti V, Cole BF, Viale G, et al. Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23\u201301): 10-year follow-up of a randomised, controlled phase 3 trial. Lancet Oncol. 2018;19(10):1385\u201393. https:\/\/doi.org\/10.1016\/S1470-2045(18)30380-2.","journal-title":"Lancet Oncol"},{"key":"15182_CR35","doi-asserted-by":"crossref","unstructured":"Mamounas E, Bandos H, White J, et al. GS02-07: loco-regional irradiation in patients with biopsy-proven axillary node involvement at presentation who become pathologically node-negative after neoadjuvant chemotherapy: primary outcomes of NRG Oncology\/NSABP B-51\/RTOG 1304. Presented at: San Antonio Breast Cancer Symposium 2023; January 12, 2023; San Antonio, Texas, United States.","DOI":"10.1158\/1538-7445.SABCS23-GS02-07"},{"issue":"10","key":"15182_CR36","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/S1470-2045(10)70207-2","volume":"11","author":"DN Krag","year":"2010","unstructured":"Krag DN, Anderson SJ, Julian TB, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol. 2010;11(10):927\u201333. https:\/\/doi.org\/10.1016\/S1470-2045(10)70207-2.","journal-title":"Lancet Oncol"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-024-15182-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-024-15182-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-024-15182-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T20:10:37Z","timestamp":1718050237000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-024-15182-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,24]]},"references-count":36,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["15182"],"URL":"https:\/\/doi.org\/10.1245\/s10434-024-15182-3","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,24]]},"assertion":[{"value":"3 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}